midazolam + omeprazole + tolbutamide

This drug combination is a clinical research tool, specifically a 'probe cocktail' used in Phase 1 drug-drug interaction (DDI) studies. It consists of three distinct pharmaceutical agents: midazolam (a benzodiazepine), tolbutamide (a sulfonylurea), and omeprazole (a proton pump inhibitor). In the context of clinical development by Johnson & Johnson Pharmaceutical Research & Development, this combination was utilized to evaluate the inhibitory or inducing effects of investigational compounds, such as the antidepressant candidate JNJ-26489112, on specific Cytochrome P450 (CYP) enzymes. Specifically, midazolam serves as a probe for CYP3A4 activity, omeprazole for CYP2C19, and tolbutamide for CYP2C9. The combination itself is not a therapeutic treatment for major depressive disorder but is used to characterize the metabolic profile and potential safety risks of drugs being developed for that indication.

Other names

3-probe substrate drug combinationCYP probe cocktailDrug combination